At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
CS-7017 +1 moredrug
Likely dose
CS-7017 0.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy
In Brief
A Phase 1 clinical trial evaluating CS-7017 and Erlotinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with erlotinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesSouth Korea
CollaboratorsICON Clinical Research
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedSep 2010
Primary CompletionDec 2011
TodayJul 2026
First PostedSep 10, 2010
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago
Interventions
CS-7017drug
CS-7017 from 0.25 mg to 0.50 mg twice daily
Erlotinibdrug
Erlotinib 150 mg once daily